Literature DB >> 20495816

Conjunctivocystorhinostomy with Jones tube--is it the surgery for children?

Pavel Komínek1, Stanislav Cervenka, Petr Matousek, Tomás Pniak, Karol Zeleník.   

Abstract

BACKGROUND: To present experience with conjunctivocystorhinostomies (CDCR) at pediatric age.
METHODS: Operative and postoperative data were collected for 15 pediatric CDCRs (aged 9 to 14.5 years) performed endonasally. Four procedures were performed bilaterally, seven unilaterally. The follow-up examinations were made every 3 months in the first year, every 6 months in the second year, and every 12 months afterwards. The patient s satisfaction with the surgery, lacrimal drainage function, and complications were evaluated. The drainage function of the lacrimal system was assessed on the basis of the history, clinical examinations, and the fluorescein dye disappearance test. The data were taken from the medical records and written questionnaires.
RESULTS: After the surgery, 12 children were very satisfied, two children partially satisfied, and one child was not satisfied (due to the loss of the tube). Full or partial functional success was found in 14 cases (93.3%); no functional success was observed in one case. The number of complications was higher than in other studies concerning adult patients. A total of 37 complications were observed in our study; most of the complications occurred in more than one of the children, and were observed in some children several times. The most frequent complications were lateral or medial malposition (25 times) and the extrusion of the tube (eight times). It was necessary to re-insert the tube in seven cases under general anaesthesia. The complications mostly occurred within the first 3 months after the surgery (seven complications during the first week, 12 complications between the 2nd and the 4th week, eight complications between the 5th and the 12th week, and three complications between the 9th and the 12th postoperative week).
CONCLUSIONS: CDCR appears to be a reasonable procedure in children over 10 years old. Experience in lacrimal surgery (pediatric dacryocystorhinostomy, CDCR in adults), and good cooperation and compliance of children are a fundamental assumption for successful pediatric CDCR.

Entities:  

Mesh:

Year:  2010        PMID: 20495816     DOI: 10.1007/s00417-010-1395-9

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  9 in total

1.  Jones' lacrimal canalicular bypass tubes: twenty-five years' experience.

Authors:  G E Rose; R A Welham
Journal:  Eye (Lond)       Date:  1991       Impact factor: 3.775

2.  Conjunctivodacryocystorhinostomy tube placement with a urologic catheter.

Authors:  Pavel Komínek; Stanislav Cervenka
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2005-05       Impact factor: 1.746

Review 3.  Endoscopic dacryocystorhinostomy and conjunctivodacryocystorhinostomy.

Authors:  John J Woog; Raj Sindwani
Journal:  Otolaryngol Clin North Am       Date:  2006-10       Impact factor: 3.346

4.  Endoscopic conjunctivodacryocystorhinostomy with Jones tube placement.

Authors:  W L Trotter; D R Meyer
Journal:  Ophthalmology       Date:  2000-06       Impact factor: 12.079

5.  Jones tube insertion in children with canalicular agenesis.

Authors:  S R Klapper; D R Jordan
Journal:  Ophthalmic Surg Lasers       Date:  1999-06

6.  Patient dissatisfaction after functionally successful conjunctivodacryocystorhinostomy with Jones tube.

Authors:  N Rosen; I Ashkenazi; M Rosner
Journal:  Am J Ophthalmol       Date:  1994-05-15       Impact factor: 5.258

7.  Problems associated with conjunctivodacryocystorhinostomy.

Authors:  G C Sekhar; R K Dortzbach; R S Gonnering; B N Lemke
Journal:  Am J Ophthalmol       Date:  1991-11-15       Impact factor: 5.258

8.  Lacrimal canalicular bypass surgery with the Lester Jones tube.

Authors:  Charmaine Lim; Peter Martin; Ross Benger; Gina Kourt; Raf Ghabrial
Journal:  Am J Ophthalmol       Date:  2004-01       Impact factor: 5.258

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.